GlassScriptPhysician profile
Zaffar A Rizvi
NPI 1730257056
$6,263.38
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,564 · 2020: $1,644 · 2021: $2,055.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,025.90 | 2019-2021 | |
| Alkermes, INC. | $990.66 | 2019-2021 | |
| Lundbeck LLC | $928.86 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $562.85 | 2019-2021 | |
| Allergan, INC. | $550.69 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $465.62 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $299.81 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $297.61 | 2020-2021 | |
| Eisai INC. | $199.48 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $192.60 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $186.86 | 2019-2021 | |
| Abbvie INC. | $182.52 | 2021 | |
| Vanda Pharmaceuticals INC. | $102.11 | 2019-2021 | |
| Noven Therapeutics, LLC | $91.21 | 2020-2021 | |
| Bausch Health US, LLC | $48.95 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $24.04 | 2019 | |
| Noven Pharmaceuticals, INC. | $17.76 | 2020 | |
| Avanir Pharmaceuticals, INC. | $16.19 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.22 | 2019 | |
| Indivior INC. | $14.06 | 2020 | |
| Ironshore Pharmaceuticals INC. | $13.54 | 2019 | |
| Merck Sharp & Dohme LLC | $12.41 | 2021 | |
| Shire North American Group INC | $12.35 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zaffar Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.